drugset / Trial / NCT05117736

ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure

NCT05117736 ↗

RandomizedCrossoverQuadruple-blindTreatment

Summary

This study is a prospective monocentric, randomized, double-blind, placebo-controlled, crossover clinical trial to assess the efficacy of Sacubitril/Valsartan over placebo in improving exercise capacity and neurohormonal activation in adults with moderate to severe systemic RV dysfunction and NYHA class II or III symptoms.

Timeline

Start
2022-03-15
Primary completion
2023-03-01
Completion
2023-03-12

Outcome

Outcome not reported

Stopped: “The trial was prematurely terminated due to safety concerns.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sacubitril / Valsartan Unknown 50 mg Oral
Subject Sacubitril / Valsartan Unknown 100 mg Oral
Subject Sacubitril / Valsartan Unknown 200 mg Oral